268 results on '"Li, Guanzhang"'
Search Results
2. Multi-omics and pharmacological characterization of patient-derived glioma cell lines
3. Trogocytosis of CAR molecule regulates CAR-T cell dysfunction and tumor antigen escape
4. Stalled oligodendrocyte differentiation in IDH-mutant gliomas
5. Temporal and spatial stability of the EM/PM molecular subtypes in adult diffuse glioma
6. WES data from 286 diffuse gliomas under the 2021 WHO Classification of Tumors of the Central Nervous System
7. MET fusions and splicing variants convergently define a subgroup of glioma sensitive to MET inhibitors
8. Clinical characteristics and survival of glioblastoma complicated with non-central nervous system tumors
9. CACA guidelines for holistic integrative management of glioma
10. Poliovirus receptor–based chimeric antigen receptor T cells combined with NK-92 cells exert potent activity against glioblastoma
11. Blockage of EGFR/AKT and mevalonate pathways synergize the antitumor effect of temozolomide by reprogramming energy metabolism in glioblastoma
12. NCOG-05. TREATMENT STRATEGY AND SURVIVAL ANALYSIS OF PATIENTS WITH PRIMARY ADULT-TYPE DIFFUSE GLIOMA IN THE MOLECULAR ERA: A PROSPECTIVE COHORT STUDY FROM THE CGGA NETWORK
13. High-dose radiation associated with improved survival in IDH-wildtype low-grade glioma
14. A novel gene signature based on five immune checkpoint genes predicts the survival of glioma
15. FXYD2 mRNA expression represents a new independent factor that affects survival of glioma patients and predicts chemosensitivity of patients to temozolomide
16. Poliovirus receptor–based chimeric antigen receptor T cells combined with NK-92 cells exert potent activity against glioblastoma.
17. MET fusions and splicing variants is a strong adverse prognostic factor in astrocytoma, isocitrate dehydrogenase mutant
18. MET fusions and splicing variants is a strong adverse prognostic factor in astrocytoma, isocitrate dehydrogenase mutant.
19. A novel methylation signature predicts radiotherapy sensitivity in glioma
20. A new glioma grading model based on histopathology and Bone Morphogenetic Protein 2 mRNA expression
21. A computational guided, functional validation of a novel therapeutic antibody proposes Notch signaling as a clinical relevant and druggable target in glioma
22. Diffuse Isocitrate Dehydrogenase–Mutant Gliomas With Histone H3 Alterations Are Distinguished by Unique Clinical Characteristics, Molecular Expression Profile, and Survival Prognosis
23. ABCC8 mRNA expression is an independent prognostic factor for glioma and can predict chemosensitivity
24. A novel gene signature based on five glioblastoma stem-like cell relevant genes predicts the survival of primary glioblastoma
25. Figure S7 from The Landscape of Viral Expression Reveals Clinically Relevant Viruses with Potential Capability of Promoting Malignancy in Lower-Grade Glioma
26. Supplementary Figures 1-17, Supplementary Tables 1-9 from Tumor Purity as an Underlying Key Factor in Glioma
27. Multi-omics and Pharmacological Characterization of Patient-derived Glioma Cell Lines
28. TREM2 is associated with tumor immunity and implies poor prognosis in glioma
29. Additional file 1 of Stalled oligodendrocyte differentiation in IDH-mutant gliomas
30. ALDH1A3 induces mesenchymal differentiation and serves as a predictor for survival in glioblastoma
31. Radiotherapy delays malignant transformation and prolongs survival in patients with IDH-mutant gliomas
32. Clinical management and survival outcomes of patients with different molecular subtypes of diffuse gliomas in China (2011–2017): a multicenter retrospective study from CGGA
33. Corrigendum: Comprehensive analysis of the clinical and biological significances of endoplasmic reticulum stress in diffuse gliomas
34. A novel chemokine‐based signature for prediction of prognosis and therapeutic response in glioma
35. Fusion Enhancement of Color Image Based on Global Histogram Equalization.
36. Expression profile analysis of antisense long non-coding RNA identifies WDFY3-AS2 as a prognostic biomarker in diffuse glioma
37. In Vitro Validation of the Therapeutic Potential of Dendrimer-Based Nanoformulations against Tumor Stem Cells
38. Progenitor cells derived from gene‐engineered human induced pluripotent stem cells as synthetic cancer cell alternatives for in vitro pharmacology
39. An MRI radiomics approach to predict survival and tumour-infiltrating macrophages in gliomas
40. Canonical WNT pathway inhibition reduces ATP synthesis rates in glioblastoma stem cells
41. Treatment Strategy and Survival Analysis of Patients with Primary Adult-Type Diffuse Glioma in the Molecular Era: A Prospective Cohort Study from the CGGA Network
42. Glioma-related epilepsy in patients with diffuse high-grade glioma after the 2016 WHO update: seizure characteristics, risk factors, and clinical outcomes
43. Clinical characterization and immunosuppressive regulation of CD161 (KLRB1) in glioma through 916 samples
44. Galectin-9/TIM-3 as a Key Regulator of Immune Response in Gliomas With Chromosome 1p/19q Codeletion
45. Molecular Characterization and Clinical Relevance of ANXA1 in Gliomas via 1,018 Chinese Cohort Patients
46. Association of high‐dose radiotherapy with improved survival in patients with newly diagnosed low‐grade gliomas
47. NK Cell-Based Immunotherapy and Therapeutic Perspective in Gliomas
48. Comparative profiling of immune genes improves the prognoses of lower grade gliomas
49. Glycometabolic reprogramming-induced XRCC1 lactylation confers therapeutic resistance in ALDH1A3-overexpressing glioblastoma.
50. Multiomics Analysis Reveals the Prognostic Non-tumor Cell Landscape in Glioblastoma Niches
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.